The Mitsubishi Tanabe Pharma Group may engage with Patient Organisations (POs) across Europe. In accordance with the EFPIA Code. Disclosure of Transfers of Value from Pharmaceutical Companies 2019, details of Transfers of Value made to POs in Europe by the Mitsubishi Tanabe Pharma Group can be found below. 

The methodology applied in preparing and collating these figures is available here in English*

If you are a Healthcare Professional and have any questions regarding the figures disclosed, please contact: 
Finance@mt-pharma-eu.com.

2021 Transfers of Value

Interactions with PO's in 2021

 PO Name 

Funding

Country

  Description of Interaction  

 SCLERODERMA & RAYNAUD'S UK 

(SRUK)

 GBP 5,000.00 

United Kingdom

 Event Sponsorship - GBP 5,000.00 (plus VAT) 
Mitsubishi Tanabe Pharma Development America (MTDA)
SRUK Virtual Conference 2021

This virtual event was hosted by leading clinicians and researchers, covering areas of research funded by SRUK, advice on symptom management, and discussions about the future, including health and wellbeing workshops.

The sponsorship funds were used exclusively to support and fund expenses directly related to the above named event. MTDA had no control, authority or ability to influence any decisions regarding how this funding was used, for which the event organisers are solely responsible. 
In acknowledgement of the support, MTDA benefited from a thank you credit on social media, logo/name alongside SRUK on website, a half-page feature in the delegate pack and one sponsored social media post. The event did not promote any MTDA products or investigational products directly or indirectly.

 

* The Mitsubishi Tanabe Pharma Group has established legal entities in the United Kingdom, Germany and Switzerland and therefore disclosure is made according to local requirements for these countries